Paul Delmar

VarMixt: efficient variance modelling for the differential analysis of replicated gene expression data

Jean-Jacques Daudin, Stéphane Robin, Paul Delmar, 2005, Bioinform..

Use of a historical control group in a noninferiority trial assessing a new antibacterial treatment: A case study and discussion of practical implementation aspects

Emmanuel Lesaffre, Joost van Rosmalen, Paul Delmar, 2018, Pharmaceutical statistics.

Reference-based imputation methods based on conditional mean imputation

Sean Yiu, Jonathan W. Bartlett, Paul Delmar, 2021 .

Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients

James Rosinski, Paul Delmar, J. Rosinski, 2009, Molecular Cancer Therapeutics.

Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations

Federico Cappuzzo, Paul Delmar, Tudor Ciuleanu, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non–Small-Cell Lung Cancer

Paul Delmar, F. Hirsch, F. Shepherd, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Mixture model on the variance for the differential analysis of gene expression data

Jean-Jacques Daudin, Stéphane Robin, Paul Delmar, 2005 .